- Home
- BBIO vs FRT Comparison
BBIO vs FRT Comparison
Compare BBIO & FRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- FRT
- Stock Information
- Founded
- BBIO 2015
- FRT 1962
- Country
- BBIO United States
- FRT United States
- Employees
- BBIO N/A
- FRT N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- FRT Real Estate Investment Trusts
- Sector
- BBIO Health Care
- FRT Real Estate
- Exchange
- BBIO Nasdaq
- FRT Nasdaq
- Market Cap
- BBIO 10.4B
- FRT 8.4B
- IPO Year
- BBIO 2019
- FRT N/A
- Fundamental
- Price
- BBIO $61.73
- FRT $96.85
- Analyst Decision
- BBIO Strong Buy
- FRT Buy
- Analyst Count
- BBIO 18
- FRT 13
- Target Price
- BBIO $74.28
- FRT $109.77
- AVG Volume (30 Days)
- BBIO 2.7M
- FRT 672.6K
- Earning Date
- BBIO 10-29-2025
- FRT 10-31-2025
- Dividend Yield
- BBIO N/A
- FRT 4.64%
- EPS Growth
- BBIO N/A
- FRT 14.84
- EPS
- BBIO N/A
- FRT 3.95
- Revenue
- BBIO $353,780,000.00
- FRT $1,257,396,000.00
- Revenue This Year
- BBIO $123.32
- FRT $5.42
- Revenue Next Year
- BBIO $73.46
- FRT $5.19
- P/E Ratio
- BBIO N/A
- FRT $24.67
- Revenue Growth
- BBIO 62.46
- FRT 6.11
- 52 Week Low
- BBIO $21.72
- FRT $80.65
- 52 Week High
- BBIO $69.48
- FRT $118.09
- Technical
- Relative Strength Index (RSI)
- BBIO 59.65
- FRT 45.60
- Support Level
- BBIO $60.23
- FRT $95.00
- Resistance Level
- BBIO $64.44
- FRT $96.66
- Average True Range (ATR)
- BBIO 3.05
- FRT 2.04
- MACD
- BBIO 0.06
- FRT -0.25
- Stochastic Oscillator
- BBIO 53.68
- FRT 57.26
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About FRT Federal Realty Investment Trust
Federal Realty Investment Trust is a shopping center-focused retail real estate investment trust that owns high-quality properties in eight of the largest metropolitan markets. Its portfolio includes an interest in 102 properties, which includes 27.4 million square feet of retail space and 3,000 multifamily units. Federal's retail portfolio includes grocery-anchored centers, superregional centers, power centers, and mixed-use urban centers. Federal Realty has focused on owning assets in highly desirable areas with significant growth, and as a result, the average population density and average median household income are higher for its portfolio than for any other retail REIT.